Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Sep 2025 value amounting to 47.58%.

  • Ligand Pharmaceuticals' EBITDA Margin rose 4151.00% to 47.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.97%, marking a year-over-year increase of 1769.00%. This contributed to the annual value of -13.53% for FY2024, which is 2262.00% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' EBITDA Margin stood at 47.58%, which was up 168.34% from 17.73% recorded in Q2 2025.
  • Ligand Pharmaceuticals' EBITDA Margin's 5-year high stood at 66.82% during Q4 2021, with a 5-year trough of -79.89% in Q1 2025.
  • In the last 3 years, Ligand Pharmaceuticals' EBITDA Margin had a median value of 6.07% in 2024 and averaged -4.11%.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' EBITDA Margin tumbled by 10,671bps in 2022, and later spiked by 6,372bps in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' EBITDA Margin (Quarterly) stood at 66.82% in 2021, then crashed by 10,671bps to -39.89% in 2022, then soared by 2,794bps to -11.95% in 2023, then tumbled by 1,056bps to -22.51% in 2024, then skyrocketed by 4,151bps to 47.58% in 2025.
  • Its EBITDA Margin was 47.58% in Q3 2025, compared to 17.73% in Q2 2025 and -79.89% in Q1 2025.